Jessica Shing

Jessica Shing

Hong Kong

Email jessica.shing@​

Phone +852 2219 0888

Fax +852 2219 0222

LanguagesEnglish, Cantonese, Mandarin

Practice groupCorporate & Finance

When clients need help on capital market projects, particularly on initial public offerings, share placements, and other general commercial and compliance matters, they turn to Jessica. 

She has also worked on secondment in a leading multinational bank, and fully understands the value of solutions that make business sense for clients.

Education and admissions


P.C.LL., City University of Hong Kong

J.D., University of British Columbia

B.Sc. Biochemistry, University of British Columbia

Representative experience

We advised RaffAello Capital Limited, the Sole Sponsor, and  RaffAello Securities (HK) Limited, China Industrial Securities International Capital Limited, Ping An Securities Limited, and Zhongtai International Securities Limited (the Joint Bookrunners and Joint Lead Managers), on the HK$127.5 million listing and initial public offering of Tian Yuan Group Holdings Limited.

Advising CLSA, CITIC Securities, Credit Suisse, BOCOM International and CIMB Securities on the US$284m Hong Kong IPO and Rule 144A placing of Macau Legend Development Limited, one of the leading owners of entertainment and casino gaming facilities in Macau and a gaming service provider in Macau.

Advising a global consultancy firm in its acquisition of a regional remuneration and related data analytics business.

Advising a U.S.-based venture capital fund in its investment in a Chinese drone and aerospace-focused company.

Advising RaffAello Capital Limited and RaffAello Securities (HK) Limited on the US$12.7m Hong Kong IPO and Regulation S placing of Fineland Real Estate Services Group Limited, a property consultancy and agency provider based in Guangzhou and the Pearl River Delta.

Advising a Europe-based pharmaceutical MNC in its investment and strategic alliance with a regional biopharma firm to collaborate on development and commercialization of certain medications.

Advising UBS, DBS Asia Capital and CIMB Securities on the US$261m Hong Kong IPO and Rule 144A placing of Nirvana Asia, the largest integrated death care service provider in Asia.

Advising UBS as the financial adviser to SOCAM Development Limited in respect of its conditional cash offer to buy-back up to 100,000,000 shares of SOCAM Development Limited.

Advising Welling Holding Limited on its US$237m privatization by Midea International Corporation Company Limited by way of a scheme of arrangement in Hong Kong and its delisting.

Loading data